What is Aptamer Group?
Aptamer Group is an England-based biotechnology firm specializing in the development of custom affinity tools. Leveraging its proprietary Optimer platform, the company provides innovative solutions designed to meet the evolving needs of researchers and developers across the life sciences sector. Their technology facilitates new approaches in critical areas such as medical research, diagnostic development, and therapeutic innovation.
How much funding has Aptamer Group raised?
Aptamer Group has raised a total of $8.2M across 2 funding rounds:
Series A
$2.2M
Stock/Share Issuance
$6M
Series A (2018): $2.2M, investors not publicly disclosed
Stock/Share Issuance (2026): $6M, investors not publicly disclosed
What's next for Aptamer Group?
The substantial enterprise-level funding and recent strategic investment signal a period of accelerated growth and development for Aptamer Group. This capital infusion is expected to fuel the expansion of its Optimer platform's applications, potentially leading to the commercialization of new diagnostic tools and therapeutic candidates. The company is strategically positioned to capitalize on emerging opportunities within the life sciences market, aiming to solidify its standing as a key provider of advanced affinity solutions.
See full Aptamer Group company page
